Drugs / CILUPREVIR
CILUPREVIR
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02268760 | Jun → Sep 2001 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02226939 | Sep → Nov 2002 | chronic hepatitis C virus infection, cirrhosis of liver | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CILUPREVIR | ChEMBL registry synonym — accepted as the source's own label CHEMBL297884 ↗ |
| Known as | BILN 2061 ZW | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02268760 ↗ |
| Known as | BILN-2061 | ChEMBL registry synonym — accepted as the source's own label CHEMBL297884 ↗ |
| Modality | Small molecule | — CHEMBL297884 ↗ |
| Route | Oral | “given orally” NCT02226939 ↗ |